Ligand Pharmaceuticals Incorporated
LGNDNext catalyst
Qtorin rapamycin
microcystic lymphatic malformations
Get an email about LGND's next catalysts
Track Ligand Pharmaceuticals (LGND) and we email you when an FDA date moves, 7 days and 1 day before the decision when the exact day is known, and when it is announced. Free account, no card.
Plus 1 more upcoming event in our data (conference).See the timeline
2 upcoming, 1 past
Upcoming FDA decisions
Market Overview
Stock performance and key metrics
Ligand Pharmaceuticals is an American biopharmaceutical company that focuses on acquiring and developing royalty-generating assets. As of 2024, the company's portfolio included royalty rights to approximately 90 pharmaceutical products across a range of therapeutic areas. Notable products from which Ligand receives royalties include the multiple myeloma (cancer) treatments Kyprolis and Evomela, the kidney disease therapy Filspari, and the pneumococcal vaccine Vaxneuvance. The company also owns the drug development technology platform Captisol.
Websitelasofoxifene
Osteoporosis
Targretin
Alopecia Areata
MB07803
Type 2 Diabetes Mellitus
MB07133
Hepatocellular Carcinoma
bexarotene
Breast Cancer
denileukin diftitox
Drug/Agent Toxicity by Tissue/Organ
PS433540
Hypertension
Aplindore
Early Stage Parkinson's Disease
Budesonide
Seasonal Allergic Rhinitis
erlotinib and bexarotene
Carcinoma, Non-small-cell Lung
Alitretinoin
Sarcoma, Kaposi
Budesonide + Azelastine
Seasonal Allergic Rhinitis
LGD-6972-15 mg
Type 2 Diabetes Mellitus
irbesartan
Hypertension
LGD-6972-10 mg
Type 2 Diabetes Mellitus
LGD-6972-5 mg
Type 2 Diabetes Mellitus
| Drug Name | Phase | Indication | Designations | Patent |
|---|---|---|---|---|
lasofoxifene | Phase 3 | Osteoporosis | - | - |
Targretin | Phase 3 | Alopecia Areata | - | - |
MB07803 | Phase 2 | Type 2 Diabetes Mellitus | - | - |
MB07133 | Phase 2 | Hepatocellular Carcinoma | - | - |
bexarotene | Phase 2 | Breast Cancer | - | - |
denileukin diftitox | Phase 2 | Drug/Agent Toxicity by Tissue/Organ | - | - |
PS433540 | Phase 2 | Hypertension | - | - |
Aplindore | Phase 2 | Early Stage Parkinson's Disease | - | - |
Budesonide | Phase 2 | Seasonal Allergic Rhinitis | - | - |
erlotinib and bexarotene | Phase 2 | Carcinoma, Non-small-cell Lung | - | - |
Alitretinoin | Phase 2 | Sarcoma, Kaposi | - | - |
Budesonide + Azelastine | Phase 2 | Seasonal Allergic Rhinitis | - | - |
LGD-6972-15 mg | Phase 2 | Type 2 Diabetes Mellitus | - | - |
irbesartan | Phase 2 | Hypertension | - | - |
LGD-6972-10 mg | Phase 2 | Type 2 Diabetes Mellitus | - | - |
LGD-6972-5 mg | Phase 2 | Type 2 Diabetes Mellitus | - | - |
Frequently asked questions
What is in Ligand Pharmaceuticals Incorporated's drug pipeline?→
CatalystAlert tracks 16 drug candidates in Ligand Pharmaceuticals Incorporated's (LGND) pipeline across Phase 3, Phase 2. Its lead program is lasofoxifene (Phase 3). Each drug's phase, indication and upcoming catalysts are listed on this page.
When is Ligand Pharmaceuticals Incorporated's next FDA catalyst?→
Ligand Pharmaceuticals Incorporated's (LGND) next tracked catalyst is a PDUFA date expected Feb 28, 2027. See the catalyst timeline on this page for the full schedule of PDUFA dates, trial readouts and FDA events.
How do I track LGND biotech catalysts?→
Add LGND to your CatalystAlert watchlist for alerts ahead of each catalyst, and follow Ligand Pharmaceuticals Incorporated's live catalyst calendar, drug pipeline and clinical-trial timeline on this page — sourced from ClinicalTrials.gov, FDA and SEC filings.